Degarelix Dosing & Reconstitution Guide

Degarelix is administered via subcutaneous injection, typically in the abdominal area. The dosing regimen begins with a loading dose of 240 mg, which consists of two 120 mg injections on day 1. Following this initial phase, a maintenance dose of 80 mg is administered every 28 days. This dosing schedule reflects findings from clinical trials that highlight the importance of achieving rapid testosterone suppression, which is critical in the context of androgen-dependent pathologies. It is important to note that the dosing regimen is based on research parameters and should not be interpreted as medical advice.

Degarelix exhibits a rapid onset of action, with testosterone suppression typically occurring within 1 to 3 days post-administration. The pharmacokinetics of this peptide indicate a half-life of approximately 53 days when administered as a subcutaneous depot, allowing for sustained therapeutic effects. Steady-state concentrations are generally reached within one month, providing a consistent level of suppression. The washout period for Degarelix is estimated to be between 2 to 3 months, which is critical when considering the timing of subsequent treatments or interventions. These pharmacokinetic parameters underscore the compound's utility in research settings focused on hormonal modulation.

Degarelix should be stored in its lyophilized form at a controlled room temperature of 25 °C (77 °F), with permissible excursions between 15-30 °C. This temperature stability is essential to maintain the integrity of the peptide prior to reconstitution. Once reconstituted, however, it is recommended that the compound be used within 1 hour to ensure optimal stability and efficacy. Researchers must adhere to these storage guidelines to prevent degradation and ensure the reliability of experimental outcomes.

When administering Degarelix, it is recommended to utilize the abdominal area for subcutaneous injections. For the initial loading dose, two separate sites should be employed to minimize local tissue reactions and ensure proper absorption. This approach is informed by clinical observations that suggest varying injection sites can enhance the tolerability of the treatment and improve the overall patient experience in clinical settings. Careful selection of injection sites is important in research applications to maintain the integrity of the data collected.

Safety evaluations of Degarelix indicate that injection site reactions, including pain, erythema, swelling, and induration, occur in approximately 40% of patients following the loading dose, although most reactions are mild to moderate and resolve within three days. Other reported side effects include hot flashes (26%) and weight gain (11%), which may impact study outcomes. Contraindications include hypersensitivity to Degarelix or any of its components, as well as its use in women and pediatric patients, for whom it is not indicated. Additionally, caution is advised in individuals with severe hepatic impairment due to limited data on safety in this population. These considerations are vital for researchers to understand the potential risks associated with the use of this compound.